Drug Trial Radar · NCT06627413
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Aug 23, 2024
Primary completion
Nov 20, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Conditions
- Schizophrenia or Schizoaffective
Interventions
Lumateperone CapsuleDrug
Lumateperone 42 mg capsule, oral administration
Lumateperone LAIDrug
Lumateperone LAI X500-E2 IM injection
Lumateperone LAIDrug
Lumateperone LAI X500-E3 IM injection
Lumateperone LAIDrug
Lumateperone LAI X500-X2 IM injection
Lumateperone LAIDrug
Lumateperone LAI X500-X5 IM injection
Lumateperone LAIDrug
Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: Cmax,oralTime frame: Day 5
- Pharmacokinetics: Cmax,IMTime frame: Day 11-60
- Pharmacokinetics: Tmax,oralTime frame: Day 5
- Pharmacokinetics: Tmax,IMTime frame: Day 11-60
- Pharmacokinetics: AUC0-t,oralTime frame: Day 5
- Pharmacokinetics: AUC0-t,IMTime frame: Day 11-60
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research, LLC
Los Alamitos, California
CenExeli Research LLC
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
Hassman Research Institute, LLC.
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.